Literature DB >> 6992266

Monocyte in vitro function in systemic lupus erythematosus (SLE). I. A clinical and immunological study.

B Svensson.   

Abstract

A previous article (34) has shown that normal monocytes cultivated in presence of several sera from patients with SLE displayed low yeast cell phagocytosis. In the present extended study it was investigated whether the level of phagocytic activity (PA) had any relation to clinical and laboratory expressions of disease activity. The results reveal that, in addition to hypocomplementaemia and cryoglobulinaemia, low PA was associated with high clinical disease activity including arthritis, rash and nephritis and high titres for anti-nDNA. It was also found that PA improved as the disease activity declined. These findings suggest that this in vitro phagocytosis test might be used as an indirect method for detecting clinically relevant circulating immune complexes in SLE. Furthermore, it might be used as a guide in the evaluation of disease activity in severe SLE. The mechanism behind impaired phagocytosis was not elucidated in this study. Inadequate opsonization of the yeast cells or blocking of the monocyte surface receptors by immune complexes were suggested as possible explanations.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6992266

Source DB:  PubMed          Journal:  Scand J Rheumatol Suppl        ISSN: 0301-3847


  5 in total

Review 1.  Impaired clearance of apoptotic cells in systemic lupus erythematosus: challenge of T and B cell tolerance.

Authors:  Susanne Kuenkele; Thomas D Beyer; Reinhard E Voll; Joachim R Kalden; Martin Herrmann
Journal:  Curr Rheumatol Rep       Date:  2003-06       Impact factor: 4.592

2.  [An impaired detection and clearance of dying cells can lead to the development of chronic autoimmunity].

Authors:  L E Munoz; M Herrmann; U S Gaipl
Journal:  Z Rheumatol       Date:  2005-09       Impact factor: 1.372

3.  Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).

Authors:  N P Hurst; G Nuki; T Wallington
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

4.  Reduced opsonisation of protein A containing Staphylococcus aureus in sera with cryoglobulins from patients with active systemic lupus erythematosus.

Authors:  O Nived; C Linder; H Odeberg; B Svensson
Journal:  Ann Rheum Dis       Date:  1985-04       Impact factor: 19.103

Review 5.  Breaking immunological tolerance in systemic lupus erythematosus.

Authors:  Elmar Pieterse; Johan van der Vlag
Journal:  Front Immunol       Date:  2014-04-09       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.